Literature DB >> 6821867

Postirradiation neurofibrosarcoma.

B S Ducatman, B W Scheithauer.   

Abstract

A known risk of radiation therapy is the induction of secondary neoplasms, most commonly osteosarcoma and fibrosarcoma. A recent addition to the list of postirradiation neoplasms is neurofibrosarcoma, a Schwann cell or fibroblastic malignancy arising in peripheral nerves, often associated with von Recklinghausen's disease. In a clinicopathologic review of 109 patients with neurofibrosarcoma seen at the Mayo Clinic from 1912 to 1981, the tumors in 12 cases were found to originate in areas that had previously been irradiated for benign or malignant disease. Seven of the 12 patients demonstrated stigmata of von Recklinghausen's disease. The mean latency period between irradiation and clinical presentation of the sarcoma was 15.6 years (range, 5-26 years). Eight patients experienced at least one recurrence; metastases were present in two, and nine patients died of their disease. The mean interval between initial diagnosis and death was 3.4 years. In summary, neurofibrosarcoma may arise secondary to radiation; animal studies on the effects of radiation on peripheral nerves support this concept. It is the authors' opinion that patients with von Recklinghausen's disease should not be unnecessarily irradiated, and that those who do receive radiation therapy should be carefully observed for the development of secondary neurofibrosarcoma.

Entities:  

Mesh:

Year:  1983        PMID: 6821867     DOI: 10.1002/1097-0142(19830315)51:6<1028::aid-cncr2820510610>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Malignant transformation of a recurrent vestibular schwannoma.

Authors:  J S Wilkinson; H Reid; G R Armstrong
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

Review 2.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

3.  [Emergent treatment of a malignant peripheral epineurial tumour].

Authors:  C Schafmayer; J-H Egberts; G Kovács; I Leuschner; J Tepel
Journal:  Chirurg       Date:  2006-07       Impact factor: 0.955

Review 4.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

5.  Brain metastases from post-radiation malignant peripheral nerve sheath tumour.

Authors:  F Fenzi; G Moretto; G Zamboni; M G Passarin; N Rizzuto
Journal:  Ital J Neurol Sci       Date:  1995-10

6.  Malignant Peripheral Nerve Sheath Tumor in Frontal Sinus, Orbital Cavity and Ethmoid Cavity.

Authors:  Jeong Hwan Lee; Nam Gyun Kim; Kyung Suk Lee; Jun Sik Kim
Journal:  Arch Craniofac Surg       Date:  2014-12-23

7.  MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.

Authors:  Meng Gong; Junrong Ma; Mi Li; Mingliang Zhou; Janet M Hock; Xijie Yu
Journal:  Neuro Oncol       Date:  2012-06-19       Impact factor: 12.300

8.  Malignant peripheral nerve sheath tumors in childhood.

Authors:  B S Ducatman; B W Scheithauer; D G Piepgras; H M Reiman
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

9.  Malignant schwannoma of the breast.

Authors:  H Hauser; A Beham; P Steindorfer; F Schmidt; M G Smola
Journal:  Langenbecks Arch Chir       Date:  1995

10.  Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.

Authors:  Carlos N Prieto-Granada; Thomas Wiesner; Jane L Messina; Achim A Jungbluth; Ping Chi; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.